logo/base Created with Sketch.
logo echosens
en
chevron Contact
Menu
English version chevron
Change region

FibroScan® powered by CAP™

CAP™ (Controlled Attenuation Parameter) is the non-invasive reference parameter used as an aid to diagnose and monitor liver steatosis.

CAP™ is available as an option.

chevron chevron
wave

Liver steatosis, why quantify it?

There is a silent epidemic of fatty liver disease in the general population, called NAFLD/NASH. The main causes of fatty liver disease are excessive alcohol consumption and/or poor diet and sedentary lifestyle.

If patients remain undiagnosed and untreated, they may go on to develop irreversible cirrhosis of the liver. If treated early with diet and lifestyle changes, the disease can be reversible.

Who is at-risk of fatty liver disease?

Most patients with the presence of a metabolic syndrome.

Risk factors and predictors of NAFLD

  • Type 2 diabetes 
  • Overweight and obesity
  • High cholesterol
  • High blood pressure
  • High triglycerides

Advantages of CAP™

CAP™ is unique, patented and validated for liver steatosis assessment2,3: 822 international and peer-reviewed articles support the use of CAP™.

CAP™ is a guiding point for doctors and patients to improve monitoring of lifestyle change and therapeutic intervention.

CAP™ is a quantitative surrogate of liver steatosis expressed in decibel per meter (db/m).

Both LSM by VCTE™ and CAP™ are measured simultaneously without lengthening the examination time.

CAP™ is available on the three FibroScan® probes (S+*, M+ and XL+).

CAP™: tried and trusted

quote

CAP™ provides a convenient and patient-friendly method to assess lipid turnover during lifestyle and dietary interventions to combat NAFLD.

Publication Arslanow et al. | Clinical and Translational Gastroenterology, 2016

quote

Lifestyle modification improves the hepatic steatosis, and CAP™ can be used to detect the improvement of hepatic steatosis during follow-up in patients with NAFLD on lifestyle modification.

Publication Paul et al. | Arq Gastroenterol, 2018

quote

The dietary intervention has a positive impact on CAP™.

Publication Arslanow et al. | Clinical and Translational Gastroenterology, 2016

chevron Discover the clinical evidence
chevron chevron

*CAP™ is not available on S+ probe in all countries.

Products in the FibroScan® range are Class IIa medical devices as defined by Directive 93/42/EEC (EC 0459). These devices are designed for use in a medical practice in order to measure liver stiffness and ultrasound attenuation in patients with liver disease. Examinations with FibroScan® device shall be performed by an operator who has been certified by the manufacturer or its approved local representative. Operators are expressly recommended to carefully read the instructions given in the user manual and on the labelling of these products. Check cost defrayal conditions with paying bodies.

References are available in our bibliography.

chevron Bibliography

Our liver health solutions

chevron Contact us